HMG-COA reductase inhibitors: An opportunity for the improvement of imatinib safety. An experimental study in rat pulmonary hypertension.

摘要: Abstract Background Co-administration of statin with imatinib is thought to result in greater improvement pulmonary arterial hypertension (PAH) than treatment alone, and hence may allow effectiveness therapy at lower doses. Methods The effects imanitib dose 20 50 mg/kg bw given together rosuvastatin or simvastatin were investigated respect right ventricle pressure (RVP), blood hypertrophy (RVH) experimental monocrotaline (MCT)-induced hypertension. Fourteen days after MCT injection, male rats treated orally for another 14 imatinib, a combination the two. Results Concurrent administration (lipophilic simvastatin, hydrophilic rosuvastatin) higher reversed MCT-induced increase RVP more each drug alone decreased RV (RV/LV + S ratio), significantly. increased was found be when co-administered simvastatin. Conclusions Statins intensify beneficial PAH, which due additional influence on decrease platelet-derived growth factor (PDGF)-induced effects. These properties used PAH reduced thereby might improve its safety profile.